pemetrexed
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Nov 1, 2006 → Nov 1, 2009
NCT ID
NCT00380718About pemetrexed
pemetrexed is a approved stage product being developed by Eli Lilly for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00380718. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035061 | Phase 2 | Completed |
| NCT03955042 | Phase 1 | Completed |
| NCT01473563 | Phase 2 | Completed |
| NCT00916630 | Phase 1 | Completed |
| NCT00732303 | Phase 2 | Terminated |
| NCT00864513 | Phase 2 | Terminated |
| NCT00520936 | Phase 2 | Completed |
| NCT00523419 | Phase 2 | Completed |
| NCT00540241 | Pre-clinical | Completed |
| NCT00497770 | Pre-clinical | Completed |
| NCT00316225 | Phase 2 | Completed |
| NCT00380718 | Approved | Completed |
| NCT00377520 | Phase 2 | Completed |
| NCT00190918 | Phase 2 | Completed |
| NCT00330915 | Phase 2 | Completed |
| NCT00109096 | Phase 2 | Completed |
| NCT00106002 | Phase 2 | Completed |
| NCT00216099 | Phase 2 | Completed |
| NCT00190983 | Phase 2 | Completed |
| NCT00216216 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer